UBS AM
ADAP

UBS AM’s Adaptimmune Therapeutics ADAP Stock Holding History

UBS AM’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-211,555
Closed -$2.55M – 2628
2015
Q4 		$2.55M Sell
211,555
-16,645
-7% -$163K ﹤0.01% 1331
2015
Q3 		$2.73M Sell
228,200
-31,900
-12% -$451K ﹤0.01% 1280
2015
Q2 		$4.77M Buy
+260,100
New +$4.46M ﹤0.01% 1069

Other funds holding ADAP

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

UBS AM's ADAP Position: Q1 2016 in Review

UBS AM sold out of Adaptimmune Therapeutics (ADAP) in Q1 2016, closing a stake of 211,555 shares — an estimated $2.55M sold.

UBS AM first reported a position in ADAP in Q2 2015 and held it in 3 quarters. The position peaked at $4.77M in Q2 2015. 49 funds tracked by Wall St. Rank hold ADAP as of Q1 2016.

  • UBS AM reported no remaining Adaptimmune Therapeutics position as of Q1 2016 after selling out during the quarter.
  • UBS AM sold 211,555 Adaptimmune Therapeutics shares in Q1 2016, an estimated $2.55M.
  • UBS AM first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 3 quarters.
  • UBS AM's Adaptimmune Therapeutics position peaked at $4.77M in Q2 2015.
  • 49 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2016.

Based on UBS AM's 13F filing for Q1 2016, filed 12 May 2016.